{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T03:41:41Z","timestamp":1794973301288,"version":"4.9.1"},"reference-count":362,"publisher":"Oxford University Press (OUP)","issue":"23","license":[{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Arterial hypertension is a leading cause of death globally. Due to ageing, the rising incidence of obesity, and socioeconomic and environmental changes, its incidence increases worldwide. Hypertension commonly coexists with Type 2 diabetes, obesity, dyslipidaemia, sedentary lifestyle, and smoking leading to risk amplification. Blood pressure lowering by lifestyle modifications and antihypertensive drugs reduce cardiovascular (CV) morbidity and mortality. Guidelines recommend dual- and triple-combination therapies using renin\u2013angiotensin system blockers, calcium channel blockers, and\/or a diuretic. Comorbidities often complicate management. New drugs such as angiotensin receptor-neprilysin inhibitors, sodium\u2013glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists improve CV and renal outcomes. Catheter-based renal denervation could offer an alternative treatment option in comorbid hypertension associated with increased sympathetic nerve activity. This review summarises the latest clinical evidence for managing hypertension with CV comorbidities.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehac395","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T08:56:33Z","timestamp":1661331393000},"page":"2066-2077","source":"Crossref","is-referenced-by-count":212,"title":["Hypertension management in patients with cardiovascular comorbidities"],"prefix":"10.1093","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1434-9556","authenticated-orcid":false,"given":"Lucas","family":"Lauder","sequence":"first","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, Universit\u00e4tsklinikum des Saarlandes, Saarland University , Kirrberger Str. 1, 66421 Homburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4425-549X","authenticated-orcid":false,"given":"Felix","family":"Mahfoud","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, Universit\u00e4tsklinikum des Saarlandes, Saarland University , Kirrberger Str. 1, 66421 Homburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0597-8318","authenticated-orcid":false,"given":"Michel","family":"Azizi","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM CIC1418 , F-75015 Paris , France"},{"name":"AP-HP, H\u00f4pital Europ\u00e9en Georges-Pompidou, Hypertension Department, DMU CARTE , F-75015 Paris , France"},{"name":"FCRIN INI-CRCT , Nancy , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-6245","authenticated-orcid":false,"given":"Deepak L","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital Heart and Vascular Center, Harvard Medical School , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7965-6296","authenticated-orcid":false,"given":"Sebastian","family":"Ewen","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, Universit\u00e4tsklinikum des Saarlandes, Saarland University , Kirrberger Str. 1, 66421 Homburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8251-4480","authenticated-orcid":false,"given":"Kazuomi","family":"Kario","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine , Tochigi , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9402-7439","authenticated-orcid":false,"given":"Gianfranco","family":"Parati","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, Cardiology Unit, University of Milano-Bicocca and Istituto Auxologico Italiano, IRCCS , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4470-7932","authenticated-orcid":false,"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[{"name":"FCRIN INI-CRCT , Nancy , France"},{"name":"Universit\u00e9 de Lorraine, INSERM, Centre d'Investigations Cliniques - Plurith\u00e9matique 14-33 and INSERM U1116 , Nancy , France"},{"name":"CHRU de Nancy , Nancy , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1765-0195","authenticated-orcid":false,"given":"Markus P","family":"Schlaich","sequence":"additional","affiliation":[{"name":"Dobney Hypertension Centre, Medical School\u2014Royal Perth Hospital Unit, Medical Research Foundation, The University of Western Australia , Perth, WA , Australia"},{"name":"Departments of Cardiology and Nephrology, Royal Perth Hospital , Perth, WA , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3731-0956","authenticated-orcid":false,"given":"Koon K","family":"Teo","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University , Hamilton, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3215-9118","authenticated-orcid":false,"given":"Raymond R","family":"Townsend","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costas","family":"Tsioufis","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens, 1st Cardiology Clinic, Hippocratio Hospital , Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8504-0831","authenticated-orcid":false,"given":"Michael A","family":"Weber","sequence":"additional","affiliation":[{"name":"SUNY Downstate College of Medicine , Brooklyn, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Weber","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Klinikum Wels-Grieskirchen , Wels , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2976-2514","authenticated-orcid":false,"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, Universit\u00e4tsklinikum des Saarlandes, Saarland University , Kirrberger Str. 1, 66421 Homburg , Germany"},{"name":"Cape Heart Institute (CHI), Faculty of Health Sciences, University of Cape Town , Cape Town , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,7]]},"reference":[{"key":"2023062017124183900_ehac395-B1","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","article-title":"Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"Murray","year":"2020","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJMoa1803180","article-title":"Effect of systolic and diastolic blood pressure on cardiovascular outcomes","volume":"381","author":"Flint","year":"2019","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B3","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1161\/01.CIR.96.1.308","article-title":"Hemodynamic patterns of age-related changes in blood pressure: The Framingham Heart Study","volume":"96","author":"Franklin","year":"1997","journal-title":"Circulation"},{"key":"2023062017124183900_ehac395-B4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0140-6736(16)31919-5","article-title":"Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants","volume":"389","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2017","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B5","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jama.287.8.1003","article-title":"Residual lifetime risk for developing hypertension in middle-aged women and men","volume":"287","author":"Vasan","year":"2002","journal-title":"JAMA"},{"key":"2023062017124183900_ehac395-B6","doi-asserted-by":"crossref","first-page":"e0147601","DOI":"10.1371\/journal.pone.0147601","article-title":"Panethnic differences in blood pressure in Europe: a systematic review and meta-analysis","volume":"11","author":"Modesti","year":"2016","journal-title":"PLoS One"},{"key":"2023062017124183900_ehac395-B7","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1161\/HYPERTENSIONAHA.121.17570","article-title":"Racial\/ethnic disparities in hypertension prevalence, awareness, treatment, and control in the United States, 2013 to 2018","volume":"78","author":"Aggarwal","year":"2021","journal-title":"Hypertension"},{"key":"2023062017124183900_ehac395-B8","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B9","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1001\/jamacardio.2017.1421","article-title":"Systolic blood pressure reduction and risk of cardiovascular disease and mortality","volume":"2","author":"Bundy","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2023062017124183900_ehac395-B10","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(21)01921-8","article-title":"Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis","volume":"398","author":"Rahimi","year":"2021","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B11","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1161\/HYPERTENSIONAHA.120.16418","article-title":"Hypertension control in the United States 2009 to 2018: factors underlying falling control rates during 2015 to 2018 across age- and race-ethnicity groups","volume":"78","author":"Egan","year":"2021","journal-title":"Hypertension"},{"key":"2023062017124183900_ehac395-B12","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","author":"Zhou","year":"2021","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B13","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/0002-8703(91)90694-D","article-title":"Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement","volume":"121","author":"Dzau","year":"1991","journal-title":"Am Heart J"},{"key":"2023062017124183900_ehac395-B14","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B15","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/S0140-6736(14)60685-1","article-title":"Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1\u00b725 million people","volume":"383","author":"Rapsomaniki","year":"2014","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B16","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1161\/HYPERTENSIONAHA.116.07905","article-title":"Research needs to improve hypertension treatment and control in African Americans","volume":"68","author":"Whelton","year":"2016","journal-title":"Hypertension"},{"key":"2023062017124183900_ehac395-B17","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1001\/jamacardio.2020.1731","article-title":"Association of normal systolic blood pressure level with cardiovascular disease in the absence of risk factors","volume":"5","author":"Whelton","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2023062017124183900_ehac395-B18","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1161\/CIRCULATIONAHA.120.049360","article-title":"Sex differences in blood pressure associations with cardiovascular outcomes","volume":"143","author":"Ji","year":"2021","journal-title":"Circulation"},{"key":"2023062017124183900_ehac395-B19","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1136\/jech.2007.068817","article-title":"Co-occurrence of risk factors for cardiovascular disease by social class: 1958 British birth cohort","volume":"62","author":"Power","year":"2008","journal-title":"J Epidemiol Community Heal"},{"key":"2023062017124183900_ehac395-B20","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990\u20132019","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2023062017124183900_ehac395-B21","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1012848","article-title":"Lifetime risks of cardiovascular disease","volume":"366","author":"Berry","year":"2012","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B23","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0140-6736(14)62070-5","article-title":"Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data","volume":"384","author":"Sundstr\u00f6m","year":"2014","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B24","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/HJH.0000000000000881","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. Less intensive blood pressure lowering and different achieved blood pressure levels\u2014updated overview and meta-analyses of randomized trials","volume":"34","author":"Thomopoulos","year":"2016","journal-title":"J Hypertens"},{"key":"2023062017124183900_ehac395-B25","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"The SPRINT Research Group","year":"2015","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B26","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1901281","article-title":"Final report of a trial of intensive versus standard blood-pressure control","volume":"384","author":"The SPRINT Research Group","year":"2021","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B27","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B28","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"2023062017124183900_ehac395-B29","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/S0140-6736(16)31326-5","article-title":"Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study","volume":"388","author":"Vidal-Petiot","year":"2016","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B30","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1016\/S0140-6736(17)30754-7","article-title":"Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials","volume":"389","author":"B\u00f6hm","year":"2017","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B31","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0140-6736(79)91274-1","article-title":"Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension","volume":"313","author":"Stewart","year":"1979","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B32","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1093\/eurheartj\/ehz149","article-title":"Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk","volume":"40","author":"B\u00f6hm","year":"2019","journal-title":"Eur Heart J"},{"key":"2023062017124183900_ehac395-B33","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jchf.2017.09.010","article-title":"Blood pressure risk associations in heart failure","volume":"5","author":"B\u00f6hm","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2023062017124183900_ehac395-B34","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1161\/CIRCULATIONAHA.117.028307","article-title":"Reverse causality in cardiovascular epidemiological research","volume":"135","author":"Sattar","year":"2017","journal-title":"Circulation"},{"key":"2023062017124183900_ehac395-B35","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jacc.2013.09.063","article-title":"Aortic pulse wave velocity improves cardiovascular event prediction","volume":"63","author":"Ben-Shlomo","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2023062017124183900_ehac395-B36","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1161\/01.CIR.103.9.1245","article-title":"Does the relation of blood pressure to coronary heart disease risk change with aging?","volume":"103","author":"Franklin","year":"2001","journal-title":"Circulation"},{"key":"2023062017124183900_ehac395-B37","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/eurheartj\/ehaa132","article-title":"Myocardial reperfusion reverses the J-curve association of cardiovascular risk and diastolic blood pressure in patients with left ventricular dysfunction and heart failure after myocardial infarction: insights from the EPHESUS trial","volume":"41","author":"B\u00f6hm","year":"2020","journal-title":"Eur Heart J"},{"key":"2023062017124183900_ehac395-B38","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.jacc.2016.08.007","article-title":"Troponin and the J-curve of diastolic blood pressure: when lower is not better","volume":"68","author":"Bhatt","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2023062017124183900_ehac395-B39","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","article-title":"Trial of intensive blood-pressure control in older patients with hypertension","volume":"385","author":"Zhang","year":"2021","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B40","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1097\/HJH.0000000000002933","article-title":"European Society of hypertension position paper on renal denervation 2021","volume":"39","author":"Schmieder","year":"2021","journal-title":"J Hypertens"},{"key":"2023062017124183900_ehac395-B41","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1093\/eurheartj\/ehx508","article-title":"Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement)","volume":"38","author":"Ruschitzka","year":"2017","journal-title":"Eur Heart J"},{"key":"2023062017124183900_ehac395-B42","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1093\/ajh\/hpy118","article-title":"Use of prescription medications that potentially interfere with blood pressure control in new-onset hypertension and treatment-resistant hypertension","volume":"31","author":"Hwang","year":"2018","journal-title":"Am J Hypertens"},{"key":"2023062017124183900_ehac395-B43","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2023062017124183900_ehac395-B44","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1161\/HYPERTENSIONAHA.116.08398","article-title":"Physical activity and incident hypertension in African Americans","volume":"69","author":"Diaz","year":"2017","journal-title":"Hypertension"},{"key":"2023062017124183900_ehac395-B45","doi-asserted-by":"crossref","first-page":"493","DOI":"10.7326\/0003-4819-136-7-200204020-00006","article-title":"Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials","volume":"136","author":"Whelton","year":"2002","journal-title":"Ann Intern Med"},{"key":"2023062017124183900_ehac395-B46","doi-asserted-by":"crossref","first-page":"e004473","DOI":"10.1161\/JAHA.112.004473","article-title":"Exercise training for blood pressure: a systematic review and meta-analysis","volume":"2","author":"Cornelissen","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"2023062017124183900_ehac395-B47","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/HJH.0b013e3283544669","article-title":"The impact of physical activity on mortality in patients with high blood pressure","volume":"30","author":"Rossi","year":"2012","journal-title":"J Hypertens"},{"key":"2023062017124183900_ehac395-B48","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41591-020-0754-2","article-title":"Effect of salt substitution on community-wide blood pressure and hypertension incidence","volume":"26","author":"Bernabe-Ortiz","year":"2020","journal-title":"Nat Med"},{"key":"2023062017124183900_ehac395-B49","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJMoa2105675","article-title":"Effect of salt substitution on cardiovascular events and death","volume":"385","author":"Neal","year":"2021","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B50","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1161\/HYPERTENSIONAHA.119.13241","article-title":"Potassium-enriched salt substitutes as a means to lower blood pressure","volume":"75","author":"Greer","year":"2020","journal-title":"Hypertension"},{"key":"2023062017124183900_ehac395-B51","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/archinternmed.2007.66","article-title":"Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"168","author":"Wright","year":"2008","journal-title":"Arch Intern Med"},{"key":"2023062017124183900_ehac395-B52","doi-asserted-by":"crossref","first-page":"614","DOI":"10.7326\/0003-4819-141-8-200410190-00009","article-title":"Systematic review: antihypertensive drug therapy in black patients","volume":"141","author":"Brewster","year":"2004","journal-title":"Ann Intern Med"},{"key":"2023062017124183900_ehac395-B53","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3389\/fphar.2020.00564","article-title":"Gender differences in cardiovascular pharmacotherapy\u2014the example of hypertension: a mini review","volume":"11","author":"Kalibala","year":"2020","journal-title":"Front Pharmacol"},{"key":"2023062017124183900_ehac395-B54","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1093\/eurheartj\/ehn427","article-title":"Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials","volume":"29","author":"Turnbull","year":"2008","journal-title":"Eur Heart J"},{"key":"2023062017124183900_ehac395-B55","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jama.2018.10359","article-title":"Fixed low-dose triple combination antihypertensive medication vs usual care for blood pressure control in patients with mild to moderate hypertension in Sri Lanka: a randomized clinical trial","volume":"320","author":"Webster","year":"2018","journal-title":"JAMA"},{"key":"2023062017124183900_ehac395-B56","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0140-6736(21)01922-X","article-title":"Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial","volume":"398","author":"Chow","year":"2021","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B57","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B58","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ijcard.2016.12.158","article-title":"A meta-analysis of add-on use of spironolactone in patients with resistant hypertension","volume":"233","author":"Zhao","year":"2017","journal-title":"Int J Cardiol"},{"key":"2023062017124183900_ehac395-B59","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.hlc.2016.02.016","article-title":"Efficacy and safety of spironolactone in patients with resistant hypertension: a meta-analysis of randomised controlled trials","volume":"25","author":"Wang","year":"2016","journal-title":"Heart Lung Circ"},{"key":"2023062017124183900_ehac395-B60","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/10641963.2016.1246564","article-title":"Addition of spironolactone in patients with resistant hypertension: a meta-analysis of randomized controlled trials","volume":"39","author":"Liu","year":"2017","journal-title":"Clin Exp Hypertens"},{"key":"2023062017124183900_ehac395-B61","doi-asserted-by":"crossref","first-page":"e21694","DOI":"10.1097\/MD.0000000000021694","article-title":"Clinical efficacy and safety of spironolactone in patients with resistant hypertension","volume":"99","author":"Chen","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"2023062017124183900_ehac395-B62","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1097\/HJH.0000000000002523","article-title":"Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials","volume":"38","author":"Thomopoulos","year":"2020","journal-title":"J Hypertens"},{"key":"2023062017124183900_ehac395-B63","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1161\/HYPERTENSIONAHA.121.18369","article-title":"Impact of antihypertensive drug class on outcomes in SPRINT","volume":"79","author":"DeCarolis","year":"2022","journal-title":"Hypertension"},{"key":"2023062017124183900_ehac395-B64","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41569-020-0364-1","article-title":"Device-based therapies for arterial hypertension","volume":"17","author":"Lauder","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2023062017124183900_ehac395-B65","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/S0140-6736(18)30951-6","article-title":"Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial","volume":"391","author":"Kandzari","year":"2018","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B66","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/S0140-6736(18)31082-1","article-title":"Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial","volume":"391","author":"Azizi","year":"2018","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B67","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/S0140-6736(20)30554-7","article-title":"Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED pivotal): a multicentre, randomised, sham-controlled trial","volume":"395","author":"B\u00f6hm","year":"2020","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B68","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/S0140-6736(21)00788-1","article-title":"Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial","volume":"397","author":"Azizi","year":"2021","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B69","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/S0140-6736(22)00455-X","article-title":"Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial","volume":"399","author":"Mahfoud","year":"2022","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B70","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4244\/EIJ-D-19-00902","article-title":"Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation","volume":"16","author":"Townsend","year":"2020","journal-title":"EuroIntervention"},{"key":"2023062017124183900_ehac395-B71","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health effects of overweight and obesity in 195 countries over 25 years","volume":"377","author":"The GBD 2015 Obesity Collaborators","year":"2017","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B72","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1097\/00004872-199412000-00018","article-title":"Body mass index and blood pressure in Korean men and women","volume":"12","author":"Jones","year":"1994","journal-title":"J Hypertens"},{"key":"2023062017124183900_ehac395-B73","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/sj.ijo.0801854","article-title":"Body mass index, abdominal adiposity and blood pressure: consistency of their association across developing and developed countries","volume":"26","author":"Doll","year":"2002","journal-title":"Int J Obes"},{"key":"2023062017124183900_ehac395-B74","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1161\/CIRCRESAHA.116.305697","article-title":"Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms","volume":"116","author":"Hall","year":"2015","journal-title":"Circ Res"},{"key":"2023062017124183900_ehac395-B75","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1161\/01.HYP.0000101686.98973.A3","article-title":"Obesity, sleep apnea, and hypertension","volume":"42","author":"Wolk","year":"2003","journal-title":"Hypertension"},{"key":"2023062017124183900_ehac395-B76","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1056\/NEJMoa1306766","article-title":"CPAP versus oxygen in obstructive sleep apnea","volume":"370","author":"Gottlieb","year":"2014","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B77","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1001\/archinte.160.18.2847","article-title":"Impact of body weight on blood pressure with a focus on sex differences","volume":"160","author":"Wilsgaard","year":"2000","journal-title":"Arch Intern Med"},{"key":"2023062017124183900_ehac395-B78","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.amjhyper.2004.05.017","article-title":"Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled","volume":"17","author":"Bramlage","year":"2004","journal-title":"Am J Hypertens"},{"key":"2023062017124183900_ehac395-B79","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/2040622312438935","article-title":"Hypertension in women: latest findings and clinical implications","volume":"3","author":"Gudmundsdottir","year":"2012","journal-title":"Ther Adv Chronic Dis"},{"key":"2023062017124183900_ehac395-B80","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1089\/jwh.2006.15.734","article-title":"Recent changes in cardiovascular risk factors among women and men","volume":"15","author":"Kim","year":"2006","journal-title":"J Womens Health (Larchmt)"},{"key":"2023062017124183900_ehac395-B81","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1161\/01.HYP.0000094221.86888.AE","article-title":"Influence of weight reduction on blood pressure","volume":"42","author":"Neter","year":"2003","journal-title":"Hypertension"},{"key":"2023062017124183900_ehac395-B82","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1161\/CIRCULATIONAHA.121.055329","article-title":"Effects of lifestyle modification on patients with resistant hypertension: results of the TRIUMPH randomized clinical trial","volume":"144","author":"Blumenthal","year":"2021","journal-title":"Circulation"},{"key":"2023062017124183900_ehac395-B83","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0140-6736(21)01640-8","article-title":"Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials","volume":"399","author":"Shi","year":"2022","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B84","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12933-021-01366-8","article-title":"GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2023062017124183900_ehac395-B85","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.114.03062","article-title":"Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus","volume":"64","author":"Ferdinand","year":"2014","journal-title":"Hypertension"},{"key":"2023062017124183900_ehac395-B86","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/cpt.2130","article-title":"Characterizing effects of antidiabetic drugs on heart rate, systolic and diastolic blood pressure","volume":"109","author":"Maringwa","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"2023062017124183900_ehac395-B87","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B88","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors","volume":"75","author":"Zelniker","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2023062017124183900_ehac395-B89","doi-asserted-by":"crossref","first-page":"m4573","DOI":"10.1136\/bmj.m4573","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"372","author":"Palmer","year":"2021","journal-title":"BMJ"},{"key":"2023062017124183900_ehac395-B90","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1161\/01.cir.0000437739.71477.ee","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults","volume":"129","author":"Jensen","year":"2014","journal-title":"Circulation"},{"key":"2023062017124183900_ehac395-B91","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1007\/s00464-020-07555-y","article-title":"Clinical practice guidelines of the European Association for Endoscopic Surgery (EAES) on bariatric surgery: update 2020 endorsed by IFSO-EC, EASO and ESPCOP","volume":"34","author":"Di Lorenzo","year":"2020","journal-title":"Surg Endosc"},{"key":"2023062017124183900_ehac395-B92","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.2337\/dc21-S008","article-title":"8. Obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes\u20142021","volume":"44","author":"American Diabetes Association","year":"2021","journal-title":"Diabetes Care"},{"key":"2023062017124183900_ehac395-B93","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1056\/NEJMoa2003697","article-title":"Effects of diet versus gastric bypass on metabolic function in diabetes","volume":"383","author":"Yoshino","year":"2020","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B94","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/CIRCULATIONAHA.117.032130","article-title":"Effects of bariatric surgery in obese patients with hypertension","volume":"137","author":"Schiavon","year":"2018","journal-title":"Circulation"},{"key":"2023062017124183900_ehac395-B95","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-3781","article-title":"Three-year outcomes of bariatric surgery in patients with obesity and hypertension","volume":"173","author":"Schiavon","year":"2020","journal-title":"Ann Intern Med"},{"key":"2023062017124183900_ehac395-B96","doi-asserted-by":"crossref","first-page":"e49696","DOI":"10.1371\/journal.pone.0049696","article-title":"Gastric bypass surgery is followed by lowered blood pressure and increased diuresis\u2014long term results from the Swedish obese subjects (SOS) study","volume":"7","author":"Hallersund","year":"2012","journal-title":"PLoS One"},{"key":"2023062017124183900_ehac395-B97","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJMoa1200225","article-title":"Bariatric surgery versus intensive medical therapy in obese patients with diabetes","volume":"366","author":"Schauer","year":"2012","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B98","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1056\/NEJMoa1600869","article-title":"Bariatric surgery versus intensive medical therapy for diabetes\u20145-year outcomes","volume":"376","author":"Schauer","year":"2017","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B99","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/CIRCRESAHA.120.316101","article-title":"Obesity phenotypes, diabetes, and cardiovascular diseases","volume":"126","author":"Pich\u00e9","year":"2020","journal-title":"Circ Res"},{"key":"2023062017124183900_ehac395-B100","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1161\/CIRCRESAHA.118.313320","article-title":"Metabolic surgery for hypertension in patients with obesity","volume":"124","author":"Pareek","year":"2019","journal-title":"Circ Res"},{"key":"2023062017124183900_ehac395-B101","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/HYPERTENSIONAHA.113.02988","article-title":"Long-term sympathoinhibitory effects of surgically induced weight loss in severe obese patients","volume":"64","author":"Seravalle","year":"2014","journal-title":"Hypertension"},{"key":"2023062017124183900_ehac395-B102","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s11695-008-9671-z","article-title":"Laparoscopic Roux-en-Y gastric bypass and its early effect on blood pressure","volume":"19","author":"Ahmed","year":"2009","journal-title":"Obes Surg"},{"key":"2023062017124183900_ehac395-B103","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/08037051.2012.749570","article-title":"Obesity-related hypertension and its remission following gastric bypass surgery - a review of the mechanisms and predictive factors","volume":"22","author":"Adams","year":"2013","journal-title":"Blood Press"},{"key":"2023062017124183900_ehac395-B104","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1007\/s11695-016-2144-x","article-title":"Effects of bariatric surgery on mortality, cardiovascular events, and cancer outcomes in obese patients: systematic review and meta-analysis","volume":"26","author":"Zhou","year":"2016","journal-title":"Obes Surg"},{"key":"2023062017124183900_ehac395-B105","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/dom.12922","article-title":"Short- and long-term mortality after bariatric surgery: a systematic review and meta-analysis.","volume":"19","author":"Cardoso","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2023062017124183900_ehac395-B106","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.2337\/db13-1093","article-title":"Diabetes control and complications trial\/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions","volume":"62","author":"Nathan","year":"2013","journal-title":"Diabetes"},{"key":"2023062017124183900_ehac395-B107","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1161\/HYPERTENSIONAHA.117.10546","article-title":"Hypertension and diabetes mellitus","volume":"71","author":"Tsimihodimos","year":"2018","journal-title":"Hypertension"},{"key":"2023062017124183900_ehac395-B108","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00125-009-1369-9","article-title":"Masked nocturnal hypertension\u2014a novel marker of risk in type 2 diabetes","volume":"52","author":"Wijkman","year":"2009","journal-title":"Diabetologia"},{"key":"2023062017124183900_ehac395-B109","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.2337\/diabetes.47.9.1501","article-title":"Reversed circadian blood pressure rhythm is associated with occurrences of both fatal and nonfatal vascular events in NIDDM subjects","volume":"47","author":"Nakano","year":"1998","journal-title":"Diabetes"},{"key":"2023062017124183900_ehac395-B110","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11906-018-0843-5","article-title":"The role of circadian rhythms in the hypertension of diabetes mellitus and the metabolic syndrome","volume":"20","author":"Lemmer","year":"2018","journal-title":"Curr Hypertens Rep"},{"key":"2023062017124183900_ehac395-B111","doi-asserted-by":"crossref","first-page":"i717","DOI":"10.1136\/bmj.i717","article-title":"Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses","volume":"352","author":"Brunstr\u00f6m","year":"2016","journal-title":"BMJ"},{"key":"2023062017124183900_ehac395-B112","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/HJH.0000000000001276","article-title":"Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10\u2014should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials","volume":"33","author":"Thomopoulos","year":"2017","journal-title":"J Hypertens"},{"key":"2023062017124183900_ehac395-B113","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jama.2014.18574","article-title":"Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis","volume":"313","author":"Emdin","year":"2015","journal-title":"JAMA"},{"key":"2023062017124183900_ehac395-B114","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/S0140-6736(21)01920-6","article-title":"Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis","volume":"398","author":"Nazarzadeh","year":"2021","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B115","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"2023062017124183900_ehac395-B116","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"ADVANCE Collaborative Group","year":"2007","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B117","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1056\/NEJMoa1407963","article-title":"Follow-up of blood-pressure lowering and glucose control in type 2 diabetes","volume":"371","author":"Zoungas","year":"2014","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B118","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1097\/HJH.0b013e3283638b1a","article-title":"Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus","volume":"31","author":"Oxlund","year":"2013","journal-title":"J Hypertens"},{"key":"2023062017124183900_ehac395-B119","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/jhh.2015.119","article-title":"Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis","volume":"30","author":"Takahashi","year":"2016","journal-title":"J Hum Hypertens"},{"key":"2023062017124183900_ehac395-B120","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B121","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B122","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2023062017124183900_ehac395-B123","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2023062017124183900_ehac395-B124","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.mayocp.2018.02.020","article-title":"What ever happened to cardioprotection with \u03b2-blockers?","volume":"93","author":"Messerli","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"2023062017124183900_ehac395-B125","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1001\/jama.292.18.2227","article-title":"Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension","volume":"292","author":"Bakris","year":"2004","journal-title":"JAMA"},{"key":"2023062017124183900_ehac395-B126","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1161\/HYPERTENSIONAHA.111.189589","article-title":"Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome","volume":"59","author":"Ayers","year":"2012","journal-title":"Hypertension"},{"key":"2023062017124183900_ehac395-B127","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1161\/HYPERTENSIONAHA.117.09259","article-title":"Risk of cardiovascular events in patients with diabetes mellitus on \u03b2-blockers","volume":"70","author":"Tsujimoto","year":"2017","journal-title":"Hypertension"},{"key":"2023062017124183900_ehac395-B128","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.mayocp.2017.11.019","article-title":"Risk of all-cause mortality in diabetic patients taking \u03b2-blockers","volume":"93","author":"Tsujimoto","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"2023062017124183900_ehac395-B129","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B130","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/10641963.2019.1676771","article-title":"Liraglutide reduces systolic blood pressure in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials","volume":"42","author":"Zhao","year":"2020","journal-title":"Clin Exp Hypertens"},{"key":"2023062017124183900_ehac395-B131","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12902-018-0332-5","article-title":"Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials","volume":"19","author":"Zhao","year":"2019","journal-title":"BMC Endocr Disord"},{"key":"2023062017124183900_ehac395-B132","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1161\/CIRCULATIONAHA.118.037076","article-title":"Twenty-four-hour blood pressure\u2013lowering effect of a sodium-glucose cotransporter 2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension","volume":"139","author":"Kario","year":"2019","journal-title":"Circulation"},{"key":"2023062017124183900_ehac395-B133","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11906-015-0621-6","article-title":"GLP-1 agonists and blood pressure: a review of the evidence","volume":"18","author":"Goud","year":"2016","journal-title":"Curr Hypertens Rep"},{"key":"2023062017124183900_ehac395-B134","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1161\/CIRCULATIONAHA.121.053709","article-title":"Are SGLT2 inhibitors new hypertension drugs?","volume":"143","author":"Kario","year":"2021","journal-title":"Circulation"},{"key":"2023062017124183900_ehac395-B135","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation"},{"key":"2023062017124183900_ehac395-B136","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1056\/NEJMc2112411","article-title":"Empagliflozin and major renal outcomes in heart failure","volume":"385","author":"Packer","year":"2021","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B137","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B138","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B139","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B140","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension","volume":"38","author":"Tikkanen","year":"2015","journal-title":"Diabetes Care"},{"key":"2023062017124183900_ehac395-B141","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1097\/HJH.0000000000002492","article-title":"Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME","volume":"38","author":"B\u00f6hm","year":"2020","journal-title":"J Hypertens"},{"key":"2023062017124183900_ehac395-B142","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1093\/eurheartj\/ehaa496","article-title":"Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)","volume":"41","author":"Serenelli","year":"2020","journal-title":"Eur Heart J"},{"key":"2023062017124183900_ehac395-B143","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.jacc.2021.07.049","article-title":"Empagliflozin improves cardiovascular and renal outcomes in heart failure irrespective of systolic blood pressure","volume":"78","author":"B\u00f6hm","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2023062017124183900_ehac395-B144","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.120.048740","article-title":"Blood pressure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease","volume":"143","author":"Ye","year":"2021","journal-title":"Circulation"},{"key":"2023062017124183900_ehac395-B145","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1161\/CIRCULATIONAHA.117.029529","article-title":"Effects of the selective sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function and central hemodynamics in patients with type 2 diabetes mellitus","volume":"136","author":"Striepe","year":"2017","journal-title":"Circulation"},{"key":"2023062017124183900_ehac395-B146","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S2213-8587(14)70033-6","article-title":"Metabolic syndrome: a sympathetic disease?","volume":"3","author":"Schlaich","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023062017124183900_ehac395-B147","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1161\/01.CIR.0000103123.66264.FE","article-title":"Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension","volume":"108","author":"Huggett","year":"2003","journal-title":"Circulation"},{"key":"2023062017124183900_ehac395-B148","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1161\/CIRCULATIONAHA.110.991869","article-title":"Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study","volume":"123","author":"Mahfoud","year":"2011","journal-title":"Circulation"},{"key":"2023062017124183900_ehac395-B149","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1016\/j.jacc.2018.09.075","article-title":"Secretory capacity of pancreatic beta-cells is enhanced 6 months after renal denervation in hypertensive patients","volume":"72","author":"Ott","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2023062017124183900_ehac395-B150","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1161\/HYPERTENSIONAHA.111.173799","article-title":"Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea","volume":"58","author":"Witkowski","year":"2011","journal-title":"Hypertension"},{"key":"2023062017124183900_ehac395-B151","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1161\/HYPERTENSIONAHA.114.04798","article-title":"Denervation of the renal arteries in metabolic syndrome","volume":"65","author":"Verloop","year":"2015","journal-title":"Hypertension"},{"key":"2023062017124183900_ehac395-B152","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1097\/HJH.0000000000001262","article-title":"Effects of multielectrode renal denervation on elevated sympathetic nerve activity and insulin resistance in metabolic syndrome","volume":"35","author":"Tsioufis","year":"2017","journal-title":"J Hypertens"},{"key":"2023062017124183900_ehac395-B153","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1161\/HYPERTENSIONAHA.108.128413","article-title":"Blood pressure is a major risk factor for renal death","volume":"54","author":"O\u2019Seaghdha","year":"2009","journal-title":"Hypertension"},{"key":"2023062017124183900_ehac395-B154","doi-asserted-by":"crossref","first-page":"244","DOI":"10.7326\/0003-4819-139-4-200308190-00006","article-title":"Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis","volume":"139","author":"Jafar","year":"2003","journal-title":"Ann Intern Med"},{"key":"2023062017124183900_ehac395-B155","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJM199212313272704","article-title":"Sympathetic overactivity in patients with chronic renal failure","volume":"327","author":"Converse","year":"1992","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B156","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/HYPERTENSIONAHA.110.164780","article-title":"Early sympathetic activation in the initial clinical stages of chronic renal failure","volume":"57","author":"Grassi","year":"2011","journal-title":"Hypertension"},{"key":"2023062017124183900_ehac395-B157","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1161\/01.HYP.0000069699.92349.8C","article-title":"Blood pressure predicts risk of developing end-stage renal disease in men and women","volume":"41","author":"Tozawa","year":"2003","journal-title":"Hypertension"},{"key":"2023062017124183900_ehac395-B158","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1097\/HJH.0b013e328359b6a9","article-title":"Sex differences in hypertension-related renal and cardiovascular diseases in Italy","volume":"30","author":"Muiesan","year":"2012","journal-title":"J Hypertens"},{"key":"2023062017124183900_ehac395-B159","doi-asserted-by":"crossref","first-page":"642","DOI":"10.2215\/CJN.08530815","article-title":"Masked hypertension and elevated nighttime blood pressure in CKD: prevalence and association with target organ damage","volume":"11","author":"Drawz","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023062017124183900_ehac395-B160","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/S0140-6736(15)00418-3","article-title":"The double challenge of resistant hypertension and chronic kidney disease","volume":"386","author":"Rossignol","year":"2015","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B161","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0140-6736(12)61272-0","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis","volume":"380","author":"Mahmoodi","year":"2012","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B162","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJM199403313301301","article-title":"The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease","volume":"330","author":"Klahr","year":"1994","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B163","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"KDIGO 2021 Clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","author":"Cheung","year":"2021","journal-title":"Kidney Int"},{"key":"2023062017124183900_ehac395-B164","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1503\/cmaj.121468","article-title":"Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis","volume":"185","author":"Lv","year":"2013","journal-title":"Can Med Assoc J"},{"key":"2023062017124183900_ehac395-B165","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Matsushita","year":"2010","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B166","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1161\/CIRCULATIONAHA.117.028814","article-title":"Cardiorenal syndrome revisited","volume":"138","author":"Zannad","year":"2018","journal-title":"Circulation"},{"key":"2023062017124183900_ehac395-B167","doi-asserted-by":"crossref","first-page":"541","DOI":"10.7326\/0003-4819-154-8-201104190-00335","article-title":"Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier","volume":"154","author":"Upadhyay","year":"2011","journal-title":"Ann Intern Med"},{"key":"2023062017124183900_ehac395-B168","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijcard.2014.12.001","article-title":"Individual-patient visit-by-visit office and ambulatory blood pressure measurements over 24 months in patients undergoing renal denervation for hypertension","volume":"181","author":"Lambert","year":"2015","journal-title":"Int J Cardiol"},{"key":"2023062017124183900_ehac395-B169","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1681\/ASN.2017020148","article-title":"Effects of intensive BP control in CKD","volume":"28","author":"Cheung","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2023062017124183900_ehac395-B170","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/ki.2013.336","article-title":"Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease","volume":"85","author":"Hung","year":"2014","journal-title":"Kidney Int"},{"key":"2023062017124183900_ehac395-B171","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1681\/ASN.2013030285","article-title":"A randomized trial of dietary sodium restriction in CKD","volume":"24","author":"McMahon","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2023062017124183900_ehac395-B172","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa2110730","article-title":"Chlorthalidone for hypertension in advanced chronic kidney disease","volume":"385","author":"Agarwal","year":"2021","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B173","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1093\/ndt\/gfw433","article-title":"Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association\u2013European Dialysis and Transplant Association (ERA-EDTA) and the hypertension and the kidney working group of the European Society of Hypertension (ESH)","volume":"32","author":"Sarafidis","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2023062017124183900_ehac395-B174","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1161\/HYPERTENSIONAHA.108.128116","article-title":"Cardiovascular protection with antihypertensive drugs in dialysis patients","volume":"53","author":"Agarwal","year":"2009","journal-title":"Hypertension"},{"key":"2023062017124183900_ehac395-B175","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S0140-6736(09)60212-9","article-title":"Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials","volume":"373","author":"Heerspink","year":"2009","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B176","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/sdi.12369","article-title":"Antihypertensive medications in end-stage renal disease","volume":"28","author":"Denker","year":"2015","journal-title":"Semin Dial"},{"key":"2023062017124183900_ehac395-B177","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B178","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1161\/01.CIR.0000034043.16664.96","article-title":"Sympathetic nerve activity in end-stage renal disease","volume":"106","author":"Hausberg","year":"2002","journal-title":"Circulation"},{"key":"2023062017124183900_ehac395-B179","doi-asserted-by":"crossref","first-page":"e002426","DOI":"10.1161\/JAHA.115.002426","article-title":"Increased sympathetic renal innervation in hemodialysis patients is the anatomical substrate of sympathetic hyperactivity in end-stage renal disease","volume":"4","author":"Mauriello","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"2023062017124183900_ehac395-B180","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/0272-6386(95)90456-5","article-title":"Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat","volume":"26","author":"Campese","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"2023062017124183900_ehac395-B181","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/ndt\/gfab154","article-title":"Renal denervation in patients with versus without chronic kidney disease: results from the Global SYMPLICITY Registry with follow-up data of 3 years","volume":"37","author":"Ott","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2023062017124183900_ehac395-B182","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1681\/ASN.2011111062","article-title":"Renal denervation in moderate to severe CKD","volume":"23","author":"Hering","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2023062017124183900_ehac395-B183","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s10157-019-01697-7","article-title":"Effects of renal denervation on blood pressure in hypertensive patients with end-stage renal disease: a single centre experience","volume":"23","author":"Ott","year":"2019","journal-title":"Clin Exp Nephrol"},{"key":"2023062017124183900_ehac395-B184","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/HJH.0000000000002358","article-title":"Renal denervation in patients with end-stage renal disease and resistant hypertension on long-term haemodialysis","volume":"38","author":"Scalise","year":"2020","journal-title":"J Hypertens"},{"key":"2023062017124183900_ehac395-B185","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/thx.2007.086371","article-title":"Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation","volume":"63","author":"Crisafulli","year":"2008","journal-title":"Thorax"},{"key":"2023062017124183900_ehac395-B186","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1136\/thx.2009.128082","article-title":"Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care","volume":"65","author":"Feary","year":"2010","journal-title":"Thorax"},{"key":"2023062017124183900_ehac395-B187","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/bcp.12181","article-title":"\u03b2-Adrenoceptor blockers and pulmonary function in the general population: the Rotterdam Study","volume":"77","author":"Loth","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"2023062017124183900_ehac395-B188","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1378\/chest.13-1235","article-title":"Adverse respiratory effect of acute \u03b2-blocker exposure in asthma","volume":"145","author":"Morales","year":"2014","journal-title":"Chest"},{"key":"2023062017124183900_ehac395-B189","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/ejhf.647","article-title":"Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the high-risk myocardi","volume":"19","author":"Coiro","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2023062017124183900_ehac395-B190","first-page":"CD003566","article-title":"Cardioselective beta-blockers for chronic obstructive pulmonary disease","volume":"2005","author":"Salpeter","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"2023062017124183900_ehac395-B191","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1053-2498(02)00459-X","article-title":"Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma","volume":"21","author":"Kotlyar","year":"2002","journal-title":"J Heart Lung Transplant"},{"key":"2023062017124183900_ehac395-B192","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1093\/eurheartj\/ehy438","article-title":"The association between blood pressure and long-term outcomes of patients with ischaemic cardiomyopathy with and without surgical revascularization: an analysis of the STICH trial","volume":"39","author":"Andersson","year":"2018","journal-title":"Eur Heart J"},{"key":"2023062017124183900_ehac395-B193","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"2023062017124183900_ehac395-B194","doi-asserted-by":"crossref","first-page":"b1665","DOI":"10.1136\/bmj.b1665","article-title":"Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies","volume":"338","author":"Law","year":"2009","journal-title":"BMJ"},{"key":"2023062017124183900_ehac395-B195","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","author":"The Consensus Trial Study Group","year":"1987","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B196","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"The SOLVD Investigators","year":"1991","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B197","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) study investigators","volume":"342","year":"1993","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B198","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B199","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A clinical trial of the angiotensin-converting\u2013enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction","volume":"333","author":"K\u00f8ber","year":"1995","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B200","first-page":"1115","article-title":"GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per to Studio della Sopravvivenza nell\u2019Infarto Miocardico","volume":"343","year":"1994","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B201","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0140-6736(95)90865-X","article-title":"ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group","volume":"345","author":"ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group","year":"1995","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B202","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting\u2013enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"The Heart Outcomes Prevention Evaluation Study Investigators","year":"2000","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B203","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B204","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2165\/00003495-200969030-00003","article-title":"Insight into the mode of action of ACE inhibition in coronary artery disease","volume":"69","author":"Ferrari","year":"2009","journal-title":"Drugs"},{"key":"2023062017124183900_ehac395-B205","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(06)69201-5","article-title":"Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials","volume":"368","author":"Dagenais","year":"2006","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B206","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S1071-9164(99)90037-4","article-title":"Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the losartan heart failure survival study-ELITE II","volume":"5","author":"Pitt","year":"1999","journal-title":"J Card Fail"},{"key":"2023062017124183900_ehac395-B207","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B208","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B209","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B210","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B211","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Teo","year":"2008","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B212","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0140-6736(02)08090-X","article-title":"Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Lindholm","year":"2002","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B213","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1093\/eurheartj\/ehp363","article-title":"Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART study","volume":"30","author":"Sawada","year":"2009","journal-title":"Eur Heart J"},{"key":"2023062017124183900_ehac395-B214","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","article-title":"Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial","volume":"366","author":"Dahl\u00f6f","year":"2005","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B215","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jacc.2004.03.065","article-title":"Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease","volume":"44","author":"Schieffer","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2023062017124183900_ehac395-B216","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehp301","article-title":"Effect of irbesartan and enalapril in non-ST elevation acute coronary syndrome: results of the randomized, double-blind ARCHIPELAGO study","volume":"30","author":"Montalescot","year":"2009","journal-title":"Eur Heart J"},{"key":"2023062017124183900_ehac395-B217","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cardiores.2006.10.021","article-title":"ACE Inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT","volume":"73","author":"Ceconi","year":"2007","journal-title":"Cardiovasc Res"},{"key":"2023062017124183900_ehac395-B218","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archinte.166.6.659","article-title":"Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized perindopril and remodeling in elderly with acute myocardial infarction (PREAMI) study","volume":"166","author":"Ferrari","year":"2006","journal-title":"Arch Intern Med"},{"key":"2023062017124183900_ehac395-B219","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0140-6736(04)17355-8","article-title":"Atenolol in hypertension: is it a wise choice?","volume":"364","author":"Carlberg","year":"2004","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B220","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/2047487314533217","article-title":"Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: a systematic review and meta-analysis","volume":"22","author":"Belsey","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"2023062017124183900_ehac395-B221","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0002-8703(95)90281-3","article-title":"Amlodipine in chronic stable angina: results of a multicenter double-blind crossover trial","volume":"129","author":"Ezekowitz","year":"1995","journal-title":"Am Heart J"},{"key":"2023062017124183900_ehac395-B222","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/hrt.2004.057703","article-title":"Favourable long term prognosis in stable angina pectoris: an extended follow up of the angina prognosis study in Stockholm (APSIS)","volume":"92","author":"Hjemdahl","year":"2006","journal-title":"Heart"},{"key":"2023062017124183900_ehac395-B223","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","article-title":"A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The InternationalVerapamil-Trandolparil Study (INVEST): a randomized controlled trial","volume":"290","author":"Pepine","year":"2003","journal-title":"JAMA"},{"key":"2023062017124183900_ehac395-B224","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.1996.03530440037034","article-title":"The progression from hypertension to congestive heart failure","volume":"275","author":"Levy","year":"1996","journal-title":"JAMA"},{"key":"2023062017124183900_ehac395-B225","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM197210192871601","article-title":"Role of blood pressure in the development of congestive heart failure","volume":"287","author":"Kannel","year":"1972","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B226","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1161\/01.CIR.0000039105.49749.6F","article-title":"Lifetime risk for developing congestive heart failure: the Framingham Heart Study","volume":"106","author":"Lloyd-Jones","year":"2002","journal-title":"Circulation"},{"key":"2023062017124183900_ehac395-B227","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1093\/eurheartj\/ehy346","article-title":"Pulsatile arterial haemodynamics in heart failure","volume":"39","author":"Weber","year":"2018","journal-title":"Eur Heart J"},{"key":"2023062017124183900_ehac395-B228","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1161\/CIRCULATIONAHA.108.845792","article-title":"The progression of hypertensive heart disease","volume":"123","author":"Drazner","year":"2011","journal-title":"Circulation"},{"key":"2023062017124183900_ehac395-B229","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.amjcard.2003.09.050","article-title":"Development of a depressed left ventricular ejection fraction in patients with left ventricular hypertrophy and a normal ejection fraction","volume":"93","author":"Rame","year":"2004","journal-title":"Am J Cardiol"},{"key":"2023062017124183900_ehac395-B230","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.amjcard.2011.05.037","article-title":"Progression from normal to reduced left ventricular ejection fraction in patients with concentric left ventricular hypertrophy after long-term follow-up","volume":"108","author":"Krishnamoorthy","year":"2011","journal-title":"Am J Cardiol"},{"key":"2023062017124183900_ehac395-B231","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/0002-9149(92)90052-Z","article-title":"Prognostic implications of subclinical left ventricular dilatation and systolic dysfunction in men free of overt cardiovascular disease (the Framingham Heart Study)","volume":"70","author":"Lauer","year":"1992","journal-title":"Am J Cardiol"},{"key":"2023062017124183900_ehac395-B232","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B233","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1056\/NEJMcp1511175","article-title":"Heart failure with preserved ejection fraction","volume":"375","author":"Redfield","year":"2016","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B234","doi-asserted-by":"crossref","first-page":"e000144","DOI":"10.1161\/JAHA.113.000144","article-title":"Lack of reduction of left ventricular mass in treated hypertension: the Strong Heart Study","volume":"2","author":"de Simone","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"2023062017124183900_ehac395-B235","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","article-title":"Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials","volume":"362","author":"Turnbull","year":"2003","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B236","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/0140-6736(91)92589-T","article-title":"Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)","volume":"338","author":"Dahl\u00f6f","year":"1991","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B237","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1001\/jama.1991.03460240051027","article-title":"Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group","volume":"265","author":"SHEP Cooperative Research Group","year":"1991","journal-title":"JAMA"},{"key":"2023062017124183900_ehac395-B238","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/HJH.0000000000000447","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses and meta regression analyses of randomized trials","volume":"33","author":"Thomopoulos","year":"2015","journal-title":"J Hypertens"},{"key":"2023062017124183900_ehac395-B239","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/ejhf.1971","article-title":"Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a SPRINT substudy","volume":"23","author":"Vaduganathan","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2023062017124183900_ehac395-B240","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/HJH.0000000000000848","article-title":"Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure\u2014meta-analyses of randomized trials","volume":"34","author":"Thomopoulos","year":"2016","journal-title":"J Hypertens"},{"key":"2023062017124183900_ehac395-B241","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/archinternmed.2010.427","article-title":"Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk","volume":"171","author":"Sciarretta","year":"2011","journal-title":"Arch Intern Med"},{"key":"2023062017124183900_ehac395-B242","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1001\/jama.289.19.2534","article-title":"Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis","volume":"289","author":"Psaty","year":"2003","journal-title":"JAMA"},{"key":"2023062017124183900_ehac395-B243","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"2023062017124183900_ehac395-B244","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.jacc.2008.05.057","article-title":"Beta-blockers for primary prevention of heart failure in patients with hypertension","volume":"52","author":"Bangalore","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2023062017124183900_ehac395-B245","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1001\/jama.283.15.1967","article-title":"Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Collaborative Research Group","volume":"283","author":"ALLHAT Collaborative Research Group","year":"2000","journal-title":"JAMA"},{"key":"2023062017124183900_ehac395-B246","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1161\/CIRCULATIONAHA.107.762229","article-title":"Heart failure with preserved and reduced left ventricular ejection fraction in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial","volume":"118","author":"Davis","year":"2008","journal-title":"Circulation"},{"key":"2023062017124183900_ehac395-B247","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1161\/HYPERTENSIONAHA.109.136655","article-title":"Regression of left ventricular mass by antihypertensive treatment","volume":"54","author":"Fagard","year":"2009","journal-title":"Hypertension"},{"key":"2023062017124183900_ehac395-B248","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1093\/eurheartj\/ehx525","article-title":"The effect of sacubitril\/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study","volume":"38","author":"Schmieder","year":"2017","journal-title":"Eur Heart J"},{"key":"2023062017124183900_ehac395-B249","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1161\/HYPERTENSIONAHA.116.08556","article-title":"Effects of sacubitril\/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension","volume":"69","author":"Williams","year":"2017","journal-title":"Hypertension"},{"key":"2023062017124183900_ehac395-B250","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.3390\/jcm10132824","article-title":"The antihypertensive effects and safety of LCZ696 in patients with hypertension: a systemic review and meta-analysis of randomized controlled trials","volume":"10","author":"Chua","year":"2021","journal-title":"J Clin Med"},{"key":"2023062017124183900_ehac395-B251","doi-asserted-by":"crossref","first-page":"e535","DOI":"10.1161\/CIR.0000000000000450","article-title":"Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: a scientific statement from the American Heart Association","volume":"134","author":"Bozkurt","year":"2016","journal-title":"Circulation"},{"key":"2023062017124183900_ehac395-B252","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2023062017124183900_ehac395-B253","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B254","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2023062017124183900_ehac395-B255","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B256","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJM199610103351504","article-title":"Effect of amlodipine on morbidity and mortality in severe chronic heart failure","volume":"335","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B257","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0002-8703(00)90095-4","article-title":"Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction","volume":"139","author":"Udelson","year":"2000","journal-title":"Am Heart J"},{"key":"2023062017124183900_ehac395-B258","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jchf.2013.04.004","article-title":"Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy","volume":"1","author":"Packer","year":"2013","journal-title":"JACC Heart Fail"},{"key":"2023062017124183900_ehac395-B259","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1161\/01.CIR.96.3.856","article-title":"Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril","volume":"96","author":"Cohn","year":"1997","journal-title":"Circulation"},{"key":"2023062017124183900_ehac395-B260","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1388-9842(03)00163-6","article-title":"Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)","volume":"5","author":"Cohn","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"2023062017124183900_ehac395-B261","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1161\/CIRCHEARTFAILURE.113.000481","article-title":"Low-sodium DASH diet improves diastolic function and ventricular\u2013arterial coupling in hypertensive heart failure with preserved ejection fraction","volume":"6","author":"Hummel","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2023062017124183900_ehac395-B262","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B263","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0140-6736(18)31808-7","article-title":"Heart failure drug treatment","volume":"393","author":"Rossignol","year":"2019","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B264","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/S0140-6736(07)60980-5","article-title":"Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial","volume":"369","author":"Solomon","year":"2007","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B265","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0002-9149(97)00320-2","article-title":"Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction \u226540% treated with diuretics plus angiot","volume":"80","author":"Aronow","year":"1997","journal-title":"Am J Cardiol"},{"key":"2023062017124183900_ehac395-B266","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1093\/eurheartj\/ehab499","article-title":"Sacubitril\u2013valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction","volume":"42","author":"Jackson","year":"2021","journal-title":"Eur Heart J"},{"key":"2023062017124183900_ehac395-B267","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B268","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"2023062017124183900_ehac395-B269","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT\u2014new insights into regional variation","volume":"376","author":"de Denus","year":"2017","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B270","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2023062017124183900_ehac395-B271","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10741-019-09901-2","article-title":"Sympathetic activation in congestive heart failure: an updated overview","volume":"26","author":"Grassi","year":"2021","journal-title":"Heart Fail Rev"},{"key":"2023062017124183900_ehac395-B272","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/j.jacc.2017.08.056","article-title":"Renal sympathetic denervation protects the failing heart via inhibition of neprilysin activity in the kidney","volume":"70","author":"Polhemus","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2023062017124183900_ehac395-B273","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1161\/HYPERTENSIONAHA.114.03699","article-title":"Cardiac sympathetic afferent denervation attenuates cardiac remodeling and improves cardiovascular dysfunction in rats with heart failure","volume":"64","author":"Wang","year":"2014","journal-title":"Hypertension"},{"key":"2023062017124183900_ehac395-B274","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1016\/j.jacc.2018.08.2186","article-title":"Renal denervation prevents heart failure progression via inhibition of the renin-angiotensin system","volume":"72","author":"Sharp","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2023062017124183900_ehac395-B275","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jacbts.2017.03.009","article-title":"Improvement of myocardial function following catheter-based renal denervation in heart failure","volume":"2","author":"Liao","year":"2017","journal-title":"JACC Basic Transl Sci"},{"key":"2023062017124183900_ehac395-B276","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ijcard.2012.09.019","article-title":"First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study","volume":"162","year":"2013","journal-title":"Int J Cardiol"},{"key":"2023062017124183900_ehac395-B277","doi-asserted-by":"crossref","first-page":"e0149855","DOI":"10.1371\/journal.pone.0149855","article-title":"Impact of renal sympathetic denervation on left ventricular structure and function at 1-year follow-up","volume":"11","author":"Almeida","year":"2016","journal-title":"PLoS One"},{"key":"2023062017124183900_ehac395-B278","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1212\/01.WNL.0000110311.09970.83","article-title":"Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies","volume":"62","author":"Lovett","year":"2004","journal-title":"Neurology"},{"key":"2023062017124183900_ehac395-B279","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1161\/STROKEAHA.106.480988","article-title":"Risk of myocardial infarction or vascular death after first ischemic stroke","volume":"38","author":"Dhamoon","year":"2007","journal-title":"Stroke"},{"key":"2023062017124183900_ehac395-B280","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1161\/CIRCRESAHA.116.308413","article-title":"Global burden of stroke","volume":"120","author":"Feigin","year":"2017","journal-title":"Circ Res"},{"key":"2023062017124183900_ehac395-B281","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0140-6736(10)60834-3","article-title":"Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study","volume":"376","author":"O'Donnell","year":"2010","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B282","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1097\/HJH.0000000000002822","article-title":"Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke","volume":"39","author":"B\u00f6hm","year":"2021","journal-title":"J Hypertens"},{"key":"2023062017124183900_ehac395-B283","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1161\/HYPERTENSIONAHA.116.08485","article-title":"Blood pressure reduction and secondary stroke prevention","volume":"69","author":"Katsanos","year":"2017","journal-title":"Hypertension"},{"key":"2023062017124183900_ehac395-B284","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/HJH.0b013e32833f3897","article-title":"Antihypertensive treatment after first stroke in primary care: results from the General Practitioner Research Database","volume":"29","author":"Toschke","year":"2011","journal-title":"J Hypertens"},{"key":"2023062017124183900_ehac395-B285","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/01.STR.0000116183.50167.D9","article-title":"Ten-year risk of first recurrent stroke and disability after first-ever stroke in the Perth Community Stroke Study","volume":"35","author":"Hardie","year":"2004","journal-title":"Stroke"},{"key":"2023062017124183900_ehac395-B286","first-page":"e13","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"2023062017124183900_ehac395-B287","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(13)60852-1","article-title":"Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial","volume":"382","author":"The SPS3 Study Group","year":"2013","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B288","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/01.hjh.0000226212.34055.86","article-title":"Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial","volume":"24","author":"Arima","year":"2006","journal-title":"J Hypertens"},{"key":"2023062017124183900_ehac395-B289","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jcmg.2017.02.015","article-title":"Left ventricular geometry determines prognosis and reverse J-shaped relation between blood pressure and mortality in ischemic stroke patients","volume":"11","author":"Park","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"2023062017124183900_ehac395-B290","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jcmg.2017.03.013","article-title":"Left ventricular geometry, blood pressure, arterial hemodynamics, and mortality after ischemic stroke","volume":"11","author":"Gillebert","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"2023062017124183900_ehac395-B291","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1097\/HJH.0b013e328342c845","article-title":"Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial\u2212Blood Pressure Lowering Arm (ASCOT-BPLA)","volume":"29","author":"Collier","year":"2011","journal-title":"J Hypertens"},{"key":"2023062017124183900_ehac395-B292","doi-asserted-by":"crossref","first-page":"e3302","DOI":"10.1097\/MD.0000000000003302","article-title":"Comparative effectiveness of blood pressure-lowering drugs in patients who have already suffered from stroke","volume":"95","author":"Wang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2023062017124183900_ehac395-B293","doi-asserted-by":"crossref","first-page":"E344","DOI":"10.1161\/STR.0000000000000211","article-title":"Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke","volume":"50","author":"Powers","year":"2019","journal-title":"Stroke"},{"key":"2023062017124183900_ehac395-B294","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1001\/jamaneurol.2014.1646","article-title":"Midlife hypertension and 20-year cognitive change: the atherosclerosis risk in communities neurocognitive study","volume":"71","author":"Gottesman","year":"2014","journal-title":"JAMA Neurol"},{"key":"2023062017124183900_ehac395-B295","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1212\/WNL.56.12.1683","article-title":"Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study","volume":"56","author":"Kivipelto","year":"2001","journal-title":"Neurology"},{"key":"2023062017124183900_ehac395-B296","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1212\/WNL.0000000000004741","article-title":"Blood pressure from mid- to late life and risk of incident dementia","volume":"89","author":"McGrath","year":"2017","journal-title":"Neurology"},{"key":"2023062017124183900_ehac395-B297","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1161\/01.STR.0000196941.58869.2d","article-title":"Midlife pulse pressure and incidence of dementia","volume":"37","author":"Freitag","year":"2006","journal-title":"Stroke"},{"key":"2023062017124183900_ehac395-B298","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1001\/jamaneurol.2017.1658","article-title":"Associations between midlife vascular risk factors and 25-year incident dementia in the Atherosclerosis Risk in Communities (ARIC) cohort","volume":"74","author":"Gottesman","year":"2017","journal-title":"JAMA Neurol"},{"key":"2023062017124183900_ehac395-B299","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S1474-4422(14)70136-X","article-title":"Potential for primary prevention of Alzheimer\u2019s disease: an analysis of population-based data","volume":"13","author":"Norton","year":"2014","journal-title":"Lancet Neurol"},{"key":"2023062017124183900_ehac395-B300","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1001\/jama.2019.10575","article-title":"Association of midlife to late-life blood pressure patterns with incident dementia","volume":"322","author":"Walker","year":"2019","journal-title":"JAMA"},{"key":"2023062017124183900_ehac395-B301","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/jama.2015.7517","article-title":"Polypharmacy in the aging patient: management of hypertension in octogenarians","volume":"314","author":"Benetos","year":"2015","journal-title":"JAMA"},{"key":"2023062017124183900_ehac395-B302","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF03325209","article-title":"Low systolic blood pressure is associated with impaired cognitive function in the oldest old: longitudinal observations in a population-based sample 80 years and older","volume":"19","author":"Nilsson","year":"2007","journal-title":"Aging Clin Exp Res"},{"key":"2023062017124183900_ehac395-B303","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1001\/jama.281.5.438","article-title":"Current and remote blood pressure and cognitive decline","volume":"281","author":"Glynn","year":"1999","journal-title":"JAMA"},{"key":"2023062017124183900_ehac395-B304","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1161\/01.HYP.0000156744.44218.74","article-title":"Nonlinear relations of blood pressure to cognitive function","volume":"45","author":"Waldstein","year":"2005","journal-title":"Hypertension"},{"key":"2023062017124183900_ehac395-B305","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1161\/01.HYP.31.3.780","article-title":"Hypertension is related to cognitive impairment","volume":"31","author":"Kilander","year":"1998","journal-title":"Hypertension"},{"key":"2023062017124183900_ehac395-B306","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1161\/CIRCRESAHA.118.313260","article-title":"Neurovascular and cognitive dysfunction in hypertension","volume":"124","author":"Iadecola","year":"2019","journal-title":"Circ Res"},{"key":"2023062017124183900_ehac395-B307","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/HJH.0b013e3283603f53","article-title":"Antihypertensive classes, cognitive decline and incidence of dementia","volume":"31","author":"Levi Marpillat","year":"2013","journal-title":"J Hypertens"},{"key":"2023062017124183900_ehac395-B308","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1161\/CIRCULATIONAHA.110.961052","article-title":"Antihypertensive treatment and change in blood pressure are associated with the progression of white matter lesion volumes","volume":"123","author":"Godin","year":"2011","journal-title":"Circulation"},{"key":"2023062017124183900_ehac395-B309","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1474-4422(19)30393-X","article-title":"Antihypertensive medications and risk for incident dementia and Alzheimer\u2019s disease: a meta-analysis of individual participant data from prospective cohort studies","volume":"19","author":"Ding","year":"2020","journal-title":"Lancet Neurol"},{"key":"2023062017124183900_ehac395-B310","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/jama.2018.21442","article-title":"Effect of intensive vs standard blood pressure control on probable dementia","volume":"321","author":"Williamson","year":"2019","journal-title":"JAMA"},{"key":"2023062017124183900_ehac395-B311","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1161\/HYP.0000000000000053","article-title":"Impact of hypertension on cognitive function: a scientific statement from the American Heart Association","volume":"68","author":"Iadecola","year":"2016","journal-title":"Hypertension"},{"key":"2023062017124183900_ehac395-B312","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1001\/archinte.162.18.2046","article-title":"The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (syst-eur) study","volume":"162","author":"Forette","year":"2002","journal-title":"Arch Intern Med"},{"key":"2023062017124183900_ehac395-B313","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/archinte.163.9.1069","article-title":"Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease","volume":"163","author":"Tzourio","year":"2003","journal-title":"Arch Intern Med"},{"key":"2023062017124183900_ehac395-B314","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1097\/HJH.0000000000001411","article-title":"Lower dementia risk with different classes of antihypertensive medication in older patients","volume":"35","author":"van Middelaar","year":"2017","journal-title":"J Hypertens"},{"key":"2023062017124183900_ehac395-B315","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1097\/HJH.0000000000000868","article-title":"Diuretic antihypertensive drugs and incident dementia risk","volume":"34","author":"Tully","year":"2016","journal-title":"J Hypertens"},{"key":"2023062017124183900_ehac395-B316","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrcardio.2016.45","article-title":"Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis","volume":"13","author":"Ko","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"2023062017124183900_ehac395-B317","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00392-017-1123-0","article-title":"Clinical scores for outcomes of rhythm control or arrhythmia progression in patients with atrial fibrillation: a systematic review","volume":"106","author":"Deng","year":"2017","journal-title":"Clin Res Cardiol"},{"key":"2023062017124183900_ehac395-B318","doi-asserted-by":"crossref","first-page":"2N","DOI":"10.1016\/S0002-9149(98)00583-9","article-title":"Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates","volume":"82","author":"Kannel","year":"1998","journal-title":"Am J Cardiol"},{"key":"2023062017124183900_ehac395-B319","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehz234","article-title":"Long-term blood pressure trajectories and incident atrial fibrillation in women and men: the Troms\u00f8 Study","volume":"41","author":"Sharashova","year":"2020","journal-title":"Eur Heart J"},{"key":"2023062017124183900_ehac395-B320","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1161\/HYPERTENSIONAHA.117.08934","article-title":"Atrial fibrillation and hypertension","volume":"70","author":"Dzeshka","year":"2017","journal-title":"Hypertension"},{"key":"2023062017124183900_ehac395-B321","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jacc.2015.06.1313","article-title":"Cardiac fibrosis in patients with atrial fibrillation","volume":"66","author":"Dzeshka","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2023062017124183900_ehac395-B322","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jacc.2004.10.068","article-title":"Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol","volume":"45","author":"Wachtell","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2023062017124183900_ehac395-B323","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/archinte.1994.00420130036007","article-title":"Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials","volume":"154","author":"Atrial Fibrillation Investigators","year":"1994","journal-title":"Arch Intern Med"},{"key":"2023062017124183900_ehac395-B324","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1212\/01.wnl.0000267275.68538.8d","article-title":"Independent predictors of stroke in patients with atrial fibrillation: a systematic review","volume":"69","author":"Hart","year":"2007","journal-title":"Neurology"},{"key":"2023062017124183900_ehac395-B325","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1160\/TH17-07-0478","article-title":"Long-term bleeding risk prediction in \u2018real world\u2019 patients with atrial fibrillation: comparison of the HAS-BLED and ABC-bleeding risk scores","volume":"117","author":"Esteve-Pastor M","year":"2017","journal-title":"Thromb Haemost"},{"key":"2023062017124183900_ehac395-B326","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2023062017124183900_ehac395-B327","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jacc.2018.05.076","article-title":"Ideal blood pressure in patients with atrial fibrillation","volume":"72","author":"Kim","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2023062017124183900_ehac395-B328","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1093\/eurheartj\/ehaa247","article-title":"Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial","volume":"41","author":"B\u00f6hm","year":"2020","journal-title":"Eur Heart J"},{"key":"2023062017124183900_ehac395-B329","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1093\/eurheartj\/ehy877","article-title":"Effect of hypertension duration and blood pressure level on ischaemic stroke risk in atrial fibrillation: nationwide data covering the entire Korean population","volume":"40","author":"Kim","year":"2019","journal-title":"Eur Heart J"},{"key":"2023062017124183900_ehac395-B330","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1817591","article-title":"Alcohol abstinence in drinkers with atrial fibrillation","volume":"382","author":"Voskoboinik","year":"2020","journal-title":"N Engl J Med"},{"key":"2023062017124183900_ehac395-B331","first-page":"CD005049","article-title":"Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation","volume":"9","author":"Lafuente-Lafuente","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2023062017124183900_ehac395-B332","doi-asserted-by":"crossref","first-page":"373.e1","DOI":"10.1016\/j.ahj.2008.01.032","article-title":"The Drug And Pace Health cliNical Evaluation (DAPHNE) study: a randomized trial comparing sotalol versus \u03b2-blockers to treat symptomatic atrial fibrillation in patients with brady-tachycardia syndrome implanted with an antitachycardia pacemaker","volume":"156","author":"Capucci","year":"2008","journal-title":"Am Heart J"},{"key":"2023062017124183900_ehac395-B333","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1093\/eurheartj\/ehl544","article-title":"Maintenance of sinus rhythm with metoprolol CR initiated before cardioversion and repeated cardioversion of atrial fibrillation: a randomized double-blind placebo-controlled study","volume":"28","author":"Nergardh","year":"2007","journal-title":"Eur Heart J"},{"key":"2023062017124183900_ehac395-B334","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/HJH.0b013e3282f35c67","article-title":"Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial","volume":"26","author":"Schmieder","year":"2008","journal-title":"J Hypertens"},{"key":"2023062017124183900_ehac395-B335","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7326\/0003-4819-152-2-201001190-00005","article-title":"Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study","volume":"152","author":"Schaer","year":"2010","journal-title":"Ann Intern Med"},{"key":"2023062017124183900_ehac395-B336","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1093\/eurheartj\/ehr266","article-title":"Aldosterone promotes atrial fibrillation","volume":"33","author":"Reil","year":"2012","journal-title":"Eur Heart J"},{"key":"2023062017124183900_ehac395-B337","doi-asserted-by":"crossref","first-page":"H1014","DOI":"10.1152\/ajpheart.00261.2016","article-title":"Hyperaldosteronism induces left atrial systolic and diastolic dysfunction","volume":"311","author":"Reil","year":"2016","journal-title":"Am J Physiol Circ Physiol"},{"key":"2023062017124183900_ehac395-B338","doi-asserted-by":"crossref","first-page":"e016239","DOI":"10.1161\/JAHA.119.016239","article-title":"Spironolactone in atrial fibrillation with preserved cardiac fraction: the IMPRESS-AF trial","volume":"9","author":"Shantsila","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2023062017124183900_ehac395-B339","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrcardio.2013.89","article-title":"Renal sympathetic denervation: applications in hypertension and beyond","volume":"10","author":"B\u00f6hm","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"2023062017124183900_ehac395-B340","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCRESAHA.115.302522","article-title":"Renal denervation for the treatment of cardiovascular high risk-hypertension or beyond?","volume":"115","author":"B\u00f6hm","year":"2014","journal-title":"Circ Res"},{"key":"2023062017124183900_ehac395-B341","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/europace\/euy325","article-title":"Thoracoscopic vs. Catheter ablation for atrial fibrillation: long-term follow-up of the FAST randomized trial","volume":"21","author":"Castell\u00e1","year":"2019","journal-title":"Europace"},{"key":"2023062017124183900_ehac395-B342","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.jacc.2012.05.036","article-title":"A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension","volume":"60","author":"Pokushalov","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2023062017124183900_ehac395-B343","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/jama.2019.21187","article-title":"Effect of renal denervation and catheter ablation vs catheter ablation alone on atrial fibrillation recurrence among patients with paroxysmal atrial fibrillation and hypertension: the ERADICATE-AF randomized clinical trial","volume":"323","author":"Steinberg","year":"2020","journal-title":"JAMA"},{"key":"2023062017124183900_ehac395-B344","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/HJH.0000000000002335","article-title":"Catheter-based renal denervation as adjunct to pulmonary vein isolation for treatment of atrial fibrillation","volume":"38","author":"Ukena","year":"2020","journal-title":"J Hypertens"},{"key":"2023062017124183900_ehac395-B345","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0140-6736(06)69208-8","article-title":"Burden of valvular heart diseases: a population-based study","volume":"368","author":"Nkomo","year":"2006","journal-title":"Lancet"},{"key":"2023062017124183900_ehac395-B346","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1080\/08037050701343241","article-title":"Severe aortic stenosis and its association with hypertension: analysis of clinical and echocardiographic parameters","volume":"16","author":"Linhartov\u00e1","year":"2007","journal-title":"Blood Press"},{"key":"2023062017124183900_ehac395-B347","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1136\/hrt.2004.041749","article-title":"The effects of hypertension on aortic valve stenosis","volume":"91","author":"Bermejo","year":"2005","journal-title":"Heart"},{"key":"2023062017124183900_ehac395-B348","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1161\/CIRCULATIONAHA.113.005275","article-title":"Time to treat hypertension in patients with aortic stenosis","volume":"128","author":"Lindman","year":"2013","journal-title":"Circulation"},{"key":"2023062017124183900_ehac395-B349","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1093\/eurheartj\/ehy486","article-title":"Elevated blood pressure and risk of aortic valve disease: a cohort analysis of 5.4 million UK adults","volume":"39","author":"Rahimi","year":"2018","journal-title":"Eur Heart J"},{"key":"2023062017124183900_ehac395-B350","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/ehjci\/jew013","article-title":"Systolic hypertension and progression of aortic valve calcification in patients with aortic stenosis: results from the PROGRESSA study","volume":"18","author":"Tastet","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2023062017124183900_ehac395-B351","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/HJH.0000000000000477","article-title":"Cardiovascular risk in relation to a new classification of hypertensive left ventricular geometric abnormalities","volume":"33","author":"de Simone","year":"2015","journal-title":"J Hypertens"},{"key":"2023062017124183900_ehac395-B352","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1161\/01.HYP.0000070029.30058.59","article-title":"Symptomatic aortic stenosis","volume":"41","author":"Antonini-Canterin","year":"2003","journal-title":"Hypertension"},{"key":"2023062017124183900_ehac395-B353","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/HYPERTENSIONAHA.112.194878","article-title":"Hypertension in aortic stenosis","volume":"60","author":"Rieck","year":"2012","journal-title":"Hypertension"},{"key":"2023062017124183900_ehac395-B354","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/ehjcvp\/pvaa040","article-title":"Management of patients with combined arterial hypertension and aortic valve stenosis: a consensus document from the Council on Hypertension and Council on Valvular Heart Disease of the European Society of Cardiology, the European Association of Cardiovasc","volume":"7","author":"Mancusi","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2023062017124183900_ehac395-B355","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"43","author":"Vahanian","year":"2022","journal-title":"Eur Heart J"},{"key":"2023062017124183900_ehac395-B356","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1161\/CIRCULATIONAHA.115.021213","article-title":"Assessing optimal blood pressure in patients with asymptomatic aortic valve stenosis: the Simvastatin Ezetimibe in Aortic Stenosis Study (SEAS)","volume":"134","author":"Nielsen","year":"2016","journal-title":"Circulation"},{"key":"2023062017124183900_ehac395-B357","doi-asserted-by":"crossref","first-page":"E19","DOI":"10.1016\/j.ahj.2003.10.017","article-title":"Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: symptomatic cardiac obstruction\u2013pilot study of enalapril in aortic stenosis (SCOPE-AS)","volume":"147","author":"Chockalingam","year":"2004","journal-title":"Am Heart J"},{"key":"2023062017124183900_ehac395-B358","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jacc.2011.01.063","article-title":"Impact of renin-angiotensin system blockade therapy on outcome in aortic stenosis","volume":"58","author":"Nadir","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2023062017124183900_ehac395-B359","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ijcard.2014.06.013","article-title":"Renin\u2013angiotensin system inhibition is not associated with increased sudden cardiac death, cardiovascular mortality or all-cause mortality in patients with aortic stenosis","volume":"175","author":"Bang","year":"2014","journal-title":"Int J Cardiol"},{"key":"2023062017124183900_ehac395-B360","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/ehjci\/jev043","article-title":"A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial)","volume":"16","author":"Bull","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2023062017124183900_ehac395-B361","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijcard.2015.04.083","article-title":"Beta-blockers can improve survival in medically-treated patients with severe symptomatic aortic stenosis","volume":"190","author":"Rossi","year":"2015","journal-title":"Int J Cardiol"},{"key":"2023062017124183900_ehac395-B362","doi-asserted-by":"crossref","first-page":"e006709","DOI":"10.1161\/JAHA.117.006709","article-title":"Antihypertensive treatment with \u03b2-blockade in patients with asymptomatic aortic stenosis and association with cardiovascular events","volume":"6","author":"Bang","year":"2017","journal-title":"J Am Heart Assoc"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/23\/2066\/50660296\/ehac395.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/23\/2066\/50660296\/ehac395.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T14:13:08Z","timestamp":1687270388000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/44\/23\/2066\/6808663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,7]]},"references-count":362,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2022,11,7]]},"published-print":{"date-parts":[[2023,6,20]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehac395","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6,14]]},"published":{"date-parts":[[2022,11,7]]}}}